BIOREXIS PHARMACEUTICAL CORPORATION Patent applications |
Patent application number | Title | Published |
20110245178 | Exendin Fusion Proteins - The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight. | 10-06-2011 |
20110091543 | ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS - Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, but does exhibit binding to iron and/or the transferrin receptor. Such fusion proteins may be administered orally. | 04-21-2011 |
20110086768 | TRANSFERRIN FUSION PROTEIN LIBRARIES - Fusion proteins comprising a transferrin moiety and integrin binding domain and peptide libraries thereof are disclosed. The present invention includes a method of screening transferrin and integrin peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast. | 04-14-2011 |